Halifax-based biopharmaceutical company Appili Therapeutics has announced that Health Canada has approved its Phase 2 clinical trial evaluating Favipiravir as a prophylactic agent against COVID-19 outbreaks.
This will be the first clinical study to examine the use of Favipiravir for outbreak control, the company said in a statement.
Researchers will enroll about 760 subjects, both residents and staff, at 16 long-term care homes in Ontario. The National Institute on Ageing has estimated that as of May 6, some 82 percent of deaths related to COVID-19 in Canada were associated with long-term